Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Leveraging genetics to help inform drug target discovery

General Research

Researchers from the University of Oxford, together with colleagues across Europe as part of the ULTRA-DD Consortium (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) have established a novel approach to maximise the informativeness of genetic evidence for drug target prioritisation.

In a paper published today in Nature Genetics, Professor Julian Knight at the Wellcome Centre for Human Genetics and colleagues from the ULTRA-DD Consortium shows how genetics and knowledge of networks can prioritise drug targets for immune-mediated diseases. 

The Priority Index or ‘Pi’ pipeline was developed by the study first-author Dr Hai Fang to be open-source and customisable, promoting collaborative efforts to accelerate early-stage drug development. This ethos was central to the ULTRA-DD Consortium, which included academic and pharma partners through an Innovative Medicines Initiative. A web interface allows users to visualise gene priority ratings, underlying data and analysis.

Read more (Wellcome Centre for Human Genetics website)

Similar stories

Ethics in Mental Health Digital Innovations for Young People in Africa: Digital Campaign

This campaign was led by a team of 29 Early Career Researchers (ECRs) and a Young People's Advisory Group (YPAG) across five African countries. The young people wanted to share contextual and accessible information on digital mental health and ethical issues that are important to them.

The Duchess of Cornwall opens the new Marcela Botnar wing

A new building at the University of Oxford's Botnar Institute for Musculoskeletal Sciences has been opened by The Duchess of Cornwall.

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.